Partner With Us NRI

Ipca Laboratories Ltd share Price

Company details

6M Return 18.95%
1Y Return 2.86%
Mkt Cap.(Cr) 23,732.74
Volume 438,049
Div Yield 0.43%
OI Chg %
Volume 438,049

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
About The Stock

    Ipca is a fully integrated pharma company manufacturing over 350 formulations and 80 APIs with exports contributing 50% of revenues in FY21.

    • Major therapeutic segments include pain management, cardiovascular and anti-diabetics, anti-infectives, anti-malarials, which together account for 75% of revenues
    • Revenue break-up FY22 – Formulations:69% (Domestic:43%, Export:26% - Export Generic:13%, Export Institutional:5%, Export Branded:7%), API:23% (Export API:17%, Domestic API: 6%), Subsidiaries: 7%

    Revenues were in line with estimates but margins were a miss.

    • Sales were up 15.7% YoY to ₹ 1289.1 crore
    • EBITDA was at ₹ 219.3 crore, down 4.2%YoY with margins at 17%
    • Consequent PAT was at ₹ 130.2 crore (down 19.2% YoY)

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Ipca Laboratories announced Q1FY24 results:

  • Consolidated Q1FY24:
    • Net Total Income of Rs 1,632.43 crore in Q1FY24 as against Rs 1,607.85 crore in Q1FY23.
    • EBIDTA margin (before forex (gain)/loss and other income) of 18.53% in Q1FY24 as against 17.88% in Q1FY23.
    • Net Profit up 14% at Rs 162.82 crore.
  • Standalone Q1FY24:
    • Net Total Income of Rs 1,531.87 crore in Q1FY24 as against Rs 1,496.24 crore in Q1FY23.
    • Exports Income of Rs 615.26 crore in Q1FY24 as against Rs 689.41 crore in Q1FY23.
    • EBIDTA margin (before forex (gain)/loss and other income) of 19.08% in Q1FY24 as against 18.21% in Q1FY23.
    • Net Profit up 19% at Rs 166.58 crore.



Result PDF

View Other Company Results


Investment recommendation
Call Date
20 Apr 2023
Entry Price 815.00
Target Price 940.00
3 Month


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Ipca Laboratories Ltd Stocks COMPARISION


Equity Capital: 5,842.02 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 16,852.71 -20,671.82
LAST 3M 52,922.55 -3,405.64
LAST 6M 58,662.39 139,660.95
LAST 12M 135,235.34 165,245.59

Ipca Laboratories Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Ipca Laboratories Ltd is a pharmaceutical company based in India. On October 19, 1949, the company was incorporated in Mumbai under the name The Indian Pharmaceutical Combine Association Limited. The company was named Ipca laboratories Ltd in 1964, and then it was changed to Ipca Laboratories Private Limited. However, in 1988, it was again changed back to Ipca Laboratories Ltd.

    Ipca laboratories Ltd is listed on the Bombay Stock Exchange with the code 524494 and on the National Stock Exchange with the symbol IPCALAB. The company had a market capitalisation of Rs 22,016 crore on November 18, 2022.

    Ipca Laboratories Ltd manufactures over 350 formulations and 80 active pharmaceutical ingredients (APIs). It has 17 manufacturing units across India, and its products are exported to 100 countries. Some APIs that Ipca Laboratories Ltd manufactures are Atenolol, Chloroquine phosphate, Chlorthalidone, Furosemide, and Hydroxychloroquine sulfate. The company has introduced a number of medicine brands, such as Zerodo, Perinorm, Tenoric, Lumerax, and Folitrax, to name a few. The subsidiary companies of Ipca laboratories Ltd are Ipca Pharmaceuticals Inc, Ipca laboratories (UK) Ltd, and Tonira Exports Ltd.

    On November 17, 2022, Ipca Laboratories Ltd’s share price closed at Rs 867.80. The share prices of Ipca laboratories Ltd have risen by 52.29% over the past three years and fallen by 16.63% in the past 12 months. The share’s 52-week high was Rs 1,128.50, and the 52-week low was Rs 831.05 as of November 18, 2022.

    In the third quarter of 2022, the company’s revenue was Rs 1,601 crore, which is 0.95% more than the previous quarter. The company had the best quarter in September 2021, with a profit of Rs 250 crore. The profit in the September quarter of 2022 was Rs 144 crore.

    As of November 18, 2022, 46.29% of Ipca Laboratories Ltd’s shares are owned by the promoters, followed by mutual funds and foreign institutional investors with 29.71% and 10.55% company shares, respectively.

    Premchand Godha is the chairman and managing director of the company, Ajit Kumar Jain is the joint managing director, and Pranay Godha and Prashant Godha are executive directors.        

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code: 07730), BSE Ltd (Member Code: 103) and Member of Multi Commodity Exchange of India Ltd.(Member Code:  56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Ms. Mamta Shetty, Contact number: 022-40701022, E-mail address: complianceofficer@icicisecurities.com. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Such representations are not indicative of future results. The securities quoted are exemplary and are not recommendatory. Investors should consult their financial advisers if in doubt about whether the product is suitable for them. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Registered Address

48 Kandivli Industrial Estate, Kandivli (West), Mumbai, Maharashtra, 400067

Tel : 91-22-66474444
Email : ipca:ipca.co.in/investors:ipca.com
Website : http://www.ipca.com

Link Intime India Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 524494
Book Closure Date (Month) :
BSE Group : A
ISIN : INE571A01038

FAQ’s on Ipca Laboratories Ltd Shares

You can buy Ipca Laboratories Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Ipca Laboratories Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Oct 03, 2023 03:54 PM the closing price of Ipca Laboratories Ltd was ₹ 935.45.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Oct 03, 2023 03:54 PM, the market cap of Ipca Laboratories Ltd stood at ₹ 23,732.74.

The latest PE ratio of Ipca Laboratories Ltd as of Oct 03, 2023 03:54 PM is 48.31

The latest PB ratio of Ipca Laboratories Ltd as of Oct 03, 2023 03:54 PM is 0.25

The 52-week high of Ipca Laboratories Ltd is ₹ 955.00 while the 52-week low is ₹ 669.80

According to analyst recommendations, Ipca Laboratories Ltd has a “Buy” rating for the long term.

Download Our App

market app
market app